{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-027307","form_type":"8-K","ticker":"LIXT","cik":"0001335105","company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","filed_at":"2026-06-04T21:01:23+00:00","discovered_at":"2026-06-04T21:02:00.269171+00:00","generated_at":"2026-06-04T21:17:31.568828+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Lixte Biotechnology closes ~$16.6M registered direct offering of common stock and warrants","bullets":["Gross proceeds of ~$16.6 million from sale of 2,625,362 shares and pre-funded warrants.","Offering priced at $6.31 per common share and $6.3099 per pre-funded warrant.","Pre-funded warrants exercisable immediately at $0.0001 per share.","Net proceeds to be used for general corporate purposes and working capital.","Offering closed on June 4, 2026 under existing shelf registration statement."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-027307","json":"https://secwatch.observer/filing/0001493152-26-027307.json","markdown":"https://secwatch.observer/filing/0001493152-26-027307.md","text":"https://secwatch.observer/filing/0001493152-26-027307.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1335105/000149315226027307/0001493152-26-027307-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1335105/000149315226027307/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T21:17:31.568828+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"957b29d8833e8e93e4db401351986eef19b3f6b0","claim":"LIXTE BIOTECHNOLOGY HOLDINGS, INC. entered into Purchase Agreement with certain accredited investors valued at approximately $16.6 million (effective 2026-06-02).","evidence_excerpt":"On June 2, 2026, Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors named therein (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “Offering”), 2,366,503 shares (the “Common Shares”) of the Company’s Common Stock, par value $0.0001 per share (the “Common Stock”), and Pre-Funded Warrants (“Pre-Funded Warrants”) to purchase 258,859 shares of Common Stock, at an offering price of $6.31 per share (or $6.30 per Pre-Funded Warrant).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1335105/000149315226027307/0001493152-26-027307-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain accredited investors"},{"label":"Value","value":"approximately $16.6 million"},{"label":"Effective","value":"2026-06-02"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}